CIK 0001789972
- Non-accelerated filer
- Smaller reporting company
Cullinan Therapeutics, Inc.
Sign in to watch- Ticker
- CGEM
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 813879991
- Phone
- +1 617-410-4650
- Business address
- ONE MAIN STREET, SUITE 1350, CAMBRIDGE, MA, 02142
- Former names
- Cullinan Oncology, Inc., Cullinan Management, Inc., Cullinan Oncology, LLC
- 4 Grant or award Chief Financial Officer acquired 47,000 shares (grant or award)
- 4 Grant or award Chief Business Officer acquired 20,500 shares (grant or award)
- 4 Grant or award Chief Legal Officer acquired 47,000 shares (grant or award)
- 4 Grant or award Chief Scientific Officer acquired 38,500 shares (grant or award)
- 4 Grant or award Chief Development Officer acquired 38,500 shares (grant or award)
- 4 Grant or award Chief Medical Officer acquired 60,000 shares (grant or award)
- 5 Insider Annual Insider Trading Report
- 4 Other disposition 10% owner disposed of 6,400,000 shares (other)
- 4 Grant or award Chief Financial Officer acquired 201 shares (grant or award)
- 4 Open-market sale Michaelson Jennifer sold 4,000 shares at $13.30 ($53,200)
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 4 Open-market sale Michaelson Jennifer sold 4,000 shares at $12.40 ($49,600)
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 4 Open-market sale Chief Development Officer sold 1,385 shares at $15.01 ($20,789)
- 4 Open-market sale 10% owner sold 49,910 shares at an average $14.26 ($711,676)
- 4 Open-market sale Chief Development Officer sold 8,000 shares at $14.51 ($116,080)
- 4 Open-market sale Acting Chief Business Officer sold 20,000 shares at an average $15.18 ($303,593)
- 4 Open-market sale Acting Chief Business Officer sold 40,000 shares at an average $13.33 ($533,304)
Page 8 of 13 · 253 filings